Update in Drug Development for Chronic HBV/HDV Infection

被引：0
|
作者：
Alfaiate D. [1 ]
Negro F. [2 ,3 ]
机构：
[1] Department of Infectious Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon
[2] Division of Gastroenterology and Hepatology, Geneva University Hospitals, 4 Rue Gabrielle-Perret-Gentil, Geneva
[3] Division of Clinical Pathology, Geneva University Hospitals, Geneva
来源：
Current Hepatology Reports | 2019年 / 18卷 / 4期
关键词：
Chronic hepatitis D; Clinical trials; Hepatitis B virus; Hepatitis D virus; Therapeutics;
D O I：
10.1007/s11901-019-00503-y
中图分类号：
学科分类号：
摘要：
Purpose of Review: Chronic hepatitis D is the most severe form of viral hepatitis. Currently, no drug has been approved for its treatment and pegylated interferon alpha remains the only recommended therapy, with dismal efficiency and important side effects. This review summarizes the recent advances in drug development for chronic hepatitis D. Recent Findings: A better knowledge of virology of hepatitis D virus has led to the development of several drugs targeting different steps of the viral life cycle. Among them, bulevirtide (a viral entry inhibitor, formerly denominated as Myrcludex B), lonafarnib (a viral assembly inhibitor), REP-2139-Ca (an inhibitor of HBsAg secretion), and pegylated interferon lambda have shown promising results in phase II clinical trials. Summary: In the near future, new therapeutic options will be available for the treatment of chronic hepatitis D. However, no drug is currently under development targeting viral replication and an effective treatment strategy may require combination of several drugs. © Springer Science+Business Media, LLC, part of Springer Nature 2019.
引用
收藏
页码：522 / 530
页数：8
相关论文
共 50 条
  • [21] Relationship of chronic HBV infection, chronic HCV infection and duration of injection drug use
    Tseng, FC
    Zhang, MD
    Kral, AH
    Welzel, T
    Edlin, B
    O'Brien, T
    GASTROENTEROLOGY, 2005, 128 (04) : A750 - A750
  • [22] HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection
    Bazinet, Michel
    Anderson, Mark
    Pantea, Victor
    Placinta, Gheorghe
    Moscalu, Iurie
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Pavlina
    Iarovoi, Liviu
    Smesnoi, Valentina
    Musteata, Tatina
    Jucov, Alina
    Dittmer, Ulf
    Gersch, Jeff
    Holzmayer, Vera
    Kuhns, Mary
    Cloherty, Gavin
    Vaillant, Andrew
    HEPATOLOGY COMMUNICATIONS, 2022, 6 (08) : 1870 - 1880
  • [23] Evaluation of the safety and tolerability of transaminase flares during antiviral therapy in patients with HBeAg negative chronic HBV infection or HBV/HDV co-infection
    Bazinet, Michel
    Pantea, Victor
    Placinta, Gheorghe
    Moscalu, Iurie
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Pavlina
    Iarovoi, Liviu
    Smesnoi, Valentina
    Musteata, Tatiana
    Jucov, Alina
    Krawczyk, Adalbert
    Vaillant, Andrew
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E486 - E486
  • [24] STUDY OF HBV (RE) INFECTION IN THE COURSE OF LIVER TRANSPLANTATION IN HBV, HBV/HDV AND OCCULT HBV INFECTED PATIENTS
    Pollicino, T.
    Caccamo, L.
    Donato, M. F.
    Raffa, G.
    Rossi, G.
    Raimondo, G.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S162 - S163
  • [25] PROBLEMS IN TREATING CHRONIC HDV INFECTION
    KING, R
    LAU, JYN
    WILLIAMS, R
    JOURNAL OF HEPATOLOGY, 1992, 14 (2-3) : 407 - 407
  • [26] High levels of HDV viremia in chronic HDV infection are associated to increased risk of progression to cirrhosis and HCC development
    Romeo, Raffaella
    Foglieni, Barbara
    Casazza, Giovanni
    Spreafico, Marta
    Colombo, Massimo
    Prati, Daniele
    HEPATOLOGY, 2012, 56 : 345A - 346A
  • [27] HBV-HDV CO-INFECTION CONSTRAINS HBV GENETIC EVOLUTION IN HBSAG
    Colagrossi, L.
    Scutari, R.
    Battisti, A.
    Salpini, R.
    Pollicita, M.
    Bertoli, A.
    Minichini, C.
    Trimoulet, P.
    Fleury, H.
    Nebuloso, E.
    Longo, R.
    Cappiello, G.
    Spano, A.
    Malagnino, V.
    Sarmati, L.
    Mari, T.
    Barlattani, A.
    Iapadre, N.
    Lichtner, M.
    Mastroianni, C.
    Lenci, I.
    Baiocchi, L.
    Pasquazzi, C.
    De Sanctis, G. M.
    Lanza, A. G.
    Stanzione, M.
    Stornaiuolo, G.
    Marignani, M.
    Andreoni, M.
    Angelico, M.
    Perno, C. -F.
    Coppola, N.
    Svicher, V.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S355 - S355
  • [28] LYMPHOKINE PATTERN IN CHRONIC HEPATITIS-B VIRUS (HBV) AND HEPATITIS DELTA VIRUS (HDV) INFECTION
    MAGRIN, S
    CRAXI, A
    CARINI, C
    MESSINA, MC
    ANTONELLI, G
    AUSIELLO, C
    SPAGNOLI, G
    DIANZANI, F
    PAGLIARO, L
    PATHOPHYSIOLOGY OF THE LIVER, 1988, 786 : 99 - 107
  • [29] HBV-HDV CO-INFECTION CONSTRAINS HBV GENETIC EVOLUTION IN HBSAG
    Colagrossi, L.
    Scutari, R.
    Salpini, R.
    Battisti, A.
    Pollicita, M.
    Bertoli, A.
    Minichini, C.
    Trimoulet, P.
    Fleury, H.
    Nebuloso, E.
    De Cristofaro, M.
    Cappiello, G.
    Spano, A.
    Malagnino, V.
    Sarmati, L.
    Mari, T.
    Barlattani, A.
    Iapadre, N.
    Lichtner, M.
    Mastroianni, C.
    Lenci, I.
    Baiocchi, L.
    Pasquazzi, C.
    De Sanctis, G. Maria
    Lanza, A. G.
    Stanzione, M.
    Stornaiuolo, G.
    Marignani, M.
    Andreoni, M.
    Angelico, M.
    Perno, C. F.
    Coppola, N.
    Svicher, V.
    DIGESTIVE AND LIVER DISEASE, 2016, 48 : E47 - E48
  • [30] SIMULTANEOUS REPLICATION OF HBV AND HDV IN CHRONIC HBSAG-CARRIERS
    BAS, C
    MONJARDINO, J
    SALDANHA, J
    BARTOLONE, J
    PORRES, JC
    ORDI, J
    QUIROGA, JA
    CARRENO, V
    JOURNAL OF HEPATOLOGY, 1987, 5 : S90 - S90
12345